41 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2035
Next term end
27
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2037 · High confidence
Also notable
Ends Oct 2038 · High confidence
Also notable
Ends Feb 2038 · High confidence
Also notable
Ends Sep 2035 · High confidence
Also notable
Ends May 2036 · High confidence
Also notable
Ends Jul 2039 · High confidence
Also notable
Ends Sep 2037 · High confidence
Also notable
Ends Dec 2036 · High confidence
Modulatory Polynucleotides
US 10,584,337
Cited by 20 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2037.
Treatment of Amyotrophic Lateral Sclerosis (ALS)
US 11,434,502
Cited by 17 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2038.
Trajectory Array Guide System
US 11,497,576
Cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Chimeric Capsids
US 10,577,627
The most cited patent in this portfolio, cited by 64 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2035.
Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS)
US 11,542,506
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036.
Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS)
US 11,603,542
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039.
Closed-Ended Linear Duplex DNA for Non-Viral Gene Transfer
US 11,066,679
Cited by 13 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037.
Assays for the Detection of Aav Neutralizing Antibodies
US 10,983,110
Granted 2021. Computed term ends 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 2 to 11, 2027 · next Jan 2
- 2 fees due Mar 12 to 19, 2027 · next Mar 12
- 1 fee due Jul 2, 2027The maintenance fee for Aav Capsids with Increased Tropism to Brain Tissue (US 11,859,200) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Modulatory Polynucleotides (US 10,570,395) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 4 fees due Sep 3 to 24, 2027 · next Sep 3
- 1 fee due Oct 9, 2027The maintenance fee for Compositions and Methods for Treating Huntington's Disease (US 11,951,121) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Aadc Polynucleotides for the Treatment of Parkinson's Disease (US 11,975,056) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
The largest of its 27 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS) | 4 in force | to May 2036 |
| Aav Capsids with Increased Tropism to Brain Tissue | 3 in force | to Mar 2041 |
| Modulatory Polynucleotides (2017) | 3 in force | to Apr 2036 |
| Aadc Polynucleotides for the Treatment of Parkinson's Disease | 3 in force | to Feb 2036 |
| Aav Capsid Variants and Uses Thereof | 2 in force | to Nov 2042 |
| Compositions and Methods for Delivery of Aav | 2 in force | to Nov 2039 |
| Closed-Ended Linear Duplex DNA for Non-Viral Gene Transfer | 2 in force | to Mar 2039 |
| Chimeric Capsids | 2 in force | to May 2038 |
| Modulatory Polynucleotides (2018) | 2 in force | to May 2037 |
| Tau Binding Compounds (2024) | 1 in force | to Sep 2043 |
| Redirection of Tropism of Aav Capsids | 1 in force | to Mar 2043 |
| Frataxin Expression Constructs Having Engineered Promoters and Methods of Use Thereof | 1 in force | to Apr 2042 |
| Methods for Measuring the Potency of Aadc Viral Vectors | 1 in force | to Dec 2041 |
| Tau Binding Compounds (2023) | 1 in force | to Dec 2041 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,577,627 | Chimeric Capsids In force · High confidence | In force | High confidence | |
| US 11,027,000 | Aadc Polynucleotides for the Treatment of Parkinson's Disease In force · High confidence | In force | High confidence | |
| US 11,975,056 | Aadc Polynucleotides for the Treatment of Parkinson's Disease In force · High confidence | In force | High confidence | |
| US 10,570,395 | Modulatory Polynucleotides In force · High confidence | In force | High confidence | |
| US 10,920,227 | Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS) In force · High confidence | In force | High confidence | |
| US 11,198,873 | Modulatory Polynucleotides In force · High confidence | In force | High confidence | |
| US 12,123,002 | Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS) In force · High confidence | In force | High confidence | |
| US 10,335,466 | Aadc Polynucleotides for the Treatment of Parkinson's Disease In force · High confidence | In force | High confidence | |
| US 12,071,625 | Modulatory Polynucleotides In force · Medium confidence | In force | Medium confidence | |
| US 11,542,506 | Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS) In force · High confidence | In force | High confidence |
Also on record, not counted in the 41: 2 patents in force now held by others · 3 patents ended · 52 applications pending · 55 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.